跳至主要内容
临床试验/NCT05044975
NCT05044975已完成不适用

Improving Sleep in Gynecologic Cancer Survivors

University of Arizona4 个研究点 分布在 1 个国家目标入组 78 人开始时间: 2021年10月11日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
78
试验地点
4
主要终点
Changes in subjectively-reported sleep quality from baseline to immediately after the intervention and 3-months post-intervention

研究概览

简要总结

This purpose of this study is to learn about how to provide treatment to gynecologic cancer survivors who have difficulty sleeping.

详细描述

This study has two parts.

In Part 1, 15 gynecologic cancer survivors will receive three candidate intervention components known to reduce sleep disturbance (i.e., sleep restriction, stimulus control, systematic light exposure) simultaneously for six weeks. Participants will then complete semi-structured individual interviews to provide feedback about barriers to and facilitators of intervention adherence. Results of Part 1 will inform the design and delivery of the candidate components in Part 2.

In Part 2, a 2^3 full factorial design will be followed to randomize 80 gynecologic cancer survivors to one of eight six-week intervention conditions reflecting all possible combinations of the three candidate intervention components.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Factorial
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • History of Stage I, II, or III gynecologic cancer
  • Age 18+ years
  • English language proficiency
  • Current sleep disturbance demonstrated by a Pittsburgh Sleep Quality Index (PSQI) score > 5
  • Usual sleep onset time between 9:00PM and 3:00AM
  • Reliable telephone and Internet access

排除标准

  • Stage IV disease
  • Diagnosed or suspected psychiatric or medical condition that may interfere with participation (e.g., psychosis, dementia, bipolar disorder, abuse of alcohol or illicit substances within the past 6 months, narrow angle glaucoma, retinal disorders, epilepsy or a similar condition)
  • Diagnosed sleep apnea, narcolepsy, periodic limb movement disorder, or restless legs syndrome unless well controlled
  • Use of medications that may be contraindications for study procedures due to safety concerns or due to potential impact on intervention efficacy or assessment validity (e.g., sedatives/hypnotics), to be identified on a case-by-case basis
  • Shift worker
  • Severe physical or cognitive impairment (≥ 2 errors on a brief six-item version of the Mini Mental State Exam [MMSE] or Patient Reported Functional Status [PRFS] score > 2, which is based on the Eastern Cooperative Oncology Group [ECOG]but has been modified to be in lay language)
  • Plans to travel across 3 or more meridians/time zones during the 6 intervention weeks or plans to cross any meridians/time zones during the 2 weeks leading up to wearing an actiwatch.
  • History of a primary diagnosis of a distinct non-gynecologic or non-skin cancer other than a non-melanoma skin cancer within the 5 years prior to enrollment
  • For participants with Stage III ovarian cancer: less than 2 years post-completion of primary gynecologic cancer treatment and/or less than 60 days post-surgery. For patients with any other gynecologic cancer/stage: less than 30 days post-completion of primary gynecologic cancer treatment and/or less than 60 days post-surgical intervention (e.g., hysterectomy)
  • Have received CBT-I or systematic bright light therapy within the past 6 months

研究组 & 干预措施

Systematic light exposure

Experimental

干预措施: Systematic light exposure (Behavioral)

Sleep restriction and Systematic light exposure

Experimental

干预措施: Systematic light exposure (Behavioral)

Stimulus control and Systematic light exposure

Experimental

干预措施: Stimulus control (Behavioral)

Stimulus control and Systematic light exposure

Experimental

干预措施: Systematic light exposure (Behavioral)

Sleep Restriction

Experimental

干预措施: Sleep restriction (Behavioral)

Sleep tracking

No Intervention

Stimulus control

Experimental

干预措施: Stimulus control (Behavioral)

Sleep restriction, Stimulus control, and Systematic light exposure

Experimental

干预措施: Stimulus control (Behavioral)

Sleep restriction, Stimulus control, and Systematic light exposure

Experimental

干预措施: Sleep restriction (Behavioral)

Sleep restriction, Stimulus control, and Systematic light exposure

Experimental

干预措施: Systematic light exposure (Behavioral)

Sleep restriction and Stimulus control

Experimental

干预措施: Sleep restriction (Behavioral)

Sleep restriction and Stimulus control

Experimental

干预措施: Stimulus control (Behavioral)

Sleep restriction and Systematic light exposure

Experimental

干预措施: Sleep restriction (Behavioral)

结局指标

主要结局

Changes in subjectively-reported sleep quality from baseline to immediately after the intervention and 3-months post-intervention

时间窗: Baseline (Part 1 and Part 2 participants), immediately after the intervention (Part 1 and Part 2 participants), 3-months post-intervention (Part 2 participants only)

Subjectively-reported sleep quality over the past 7 days will be measured with the Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance questionnaire. Raw scores will be converted to T-scores with a mean of 50 and a standard deviation of 10. Higher scores indicate more of the underlying construct.

Changes in perceived impairment during wake associated with sleep problems from baseline to immediately after the intervention and 3-months post-intervention

时间窗: Baseline (Part 1 and Part 2 participants), immediately after the intervention (Part 1 and Part 2 participants), 3-months post-intervention (Part 2 participants only)

Perceived impairment during wake associated with sleep problems over the past seven days will be measured with the PROMIS Sleep-Related Impairment questionnaire. Raw scores will be converted to T-scores with a mean of 50 and a standard deviation of 10. Higher scores indicate more of the underlying construct.

Changes in objectively-measured sleep outcomes from baseline to immediately after the intervention and 3-months post-intervention

时间窗: Baseline (Part 1 and Part 2 participants), immediately after the intervention (Part 1 and Part 2 participants), 3-months post-intervention (Part 2 participants only)

Wrist actigraphy

次要结局

  • Changes in overall symptom burden from baseline to immediately after the intervention and 3-months post-intervention(Baseline (Part 1 and Part 2 participants), immediately after the intervention (Part 1 and Part 2 participants), 3-months post-intervention (Part 2 participants only))
  • Changes in symptoms of depression from baseline to immediately after the intervention and 3-months post-intervention(Baseline (Part 1 and Part 2 participants), immediately after the intervention (Part 1 and Part 2 participants), 3-months post-intervention (Part 2 participants only))
  • Changes in fatigue from baseline to immediately after the intervention and 3-months post-intervention(Baseline (Part 1 and Part 2 participants), immediately after the intervention (Part 1 and Part 2 participants), 3-months post-intervention (Part 2 participants only))
  • Changes in symptoms of anxiety from baseline to immediately after the intervention and 3-months post-intervention(Baseline (Part 1 and Part 2 participants), immediately after the intervention (Part 1 and Part 2 participants), 3-months post-intervention (Part 2 participants only))
  • Changes in health-related quality of life (HRQOL) from baseline to immediately after the intervention and 3-months post-intervention(Baseline (Part 1 and Part 2 participants), immediately after the intervention (Part 1 and Part 2 participants), 3-months post-intervention (Part 2 participants only))

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Rina Fox

Assistant Professor

University of Arizona

研究点 (4)

Loading locations...

相似试验

Improving Sleep in Gynecologic Cancer Survivors | 临床试验